To facilitate the cell-specific mRNA treatment of IBD, Veiga et al. [40] developed an antibody-modified LNP designed to target interleukin-10 (IL-10) mRNA to Ly6c+ inflammatory leukocytes. Here, IL10 is linked to inflammatory bowel disease.